Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Bard Peripheral Vascular, INC.

Approvalsnew device approved (PMA)25 Sept 2026

Bard Peripheral Vascular, INC.

25 Sept 2026: New device approved (PMA) · Liverty™ TIPS Stent Graft. Recorded in the openFDA device PMA data.

View the source record

Decided
25 Sept 2026
Device
Liverty™ TIPS Stent Graft
Specialty
Cardiovascular
Type
Original approval
Reference
P250050
Location
Tempe, AZ
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Bard Peripheral Vascular, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Bard Peripheral Vascular, INC. in our registers.

More in Cardiovascular

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.